LFCR (Lifecore Biomedical Inc.) Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Reliance on the expertise of biochemists ensures that Lifecore Biomedical (LFCR) delivers high-quality order execution, as confirmed by the base chart on GURU.Markets. The consensus EPS forecast for the coming year via 0.00 reflects the current volume of this metric. Meanwhile, Lifecore Biomedical (LFCR) is implementing eco-friendly production methods, adhering to bioethics, and focusing on organic growth without new mergers following an internal audit.

Lifecore Biomedical Inc. (LFCR): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 28.04.2023 nganti 11.11.2026

Lifecore Biomedical, Inc. (LFCR) - rincian metrik lan laporan keuangan

- kuotasi lan prakiraan analis:

Kutipan saham Lifecore Biomedical Inc.|LFCR - Rega prakiraan analis

- indikator valuasi pasar bisnis:

Nilai pasar Lifecore Biomedical|LFCR - Rega Tumbas Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Siji Saham Lifecore Biomedical|LFCR - Nilai Buku Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku lifecore.com|LFCR - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Lifecore Biomedical|LFCR - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal Lifecore Biomedical Inc.|LFCR - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Lifecore Biomedical|LFCR - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Lifecore Biomedical|Likuiditas cepet lifecore.com

- data bathi resik lan rasio valuasi:

LFCR - Bathi pungkasan|Proyeksi bathi mangsa ngarep Lifecore Biomedical|LFCR - Kapitalisasi marang bathi|Prakiraan rega marang bathi Lifecore Biomedical Inc.|LFCR - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Lifecore Biomedical|LFCR - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Lifecore Biomedical|LFCR - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan lifecore.com|LFCR - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Lifecore Biomedical

Analisis fundamental perusahaan:Lifecore Biomedical, LFCR

Investors are assessing the risk of asset overvaluation by analyzing the gap between price and actual earnings growth rates. Rigorous FDA validation of Lifecore Biomedical (LFCR) processes creates high barrier inertia, guaranteeing the stability of long-term contracts. The projected EPS growth rate measures the dynamics of Wall Street forecast revisions regarding future earnings per share. A sharp spike in this indicator often signals the formation of a bubble, warning of the risk of entering at the peak.

Analisis perusahaan pesaing